Kalaris Therapeutics (KLRS) Misses Q1 EPS by 46c

Kalaris Therapeutics (NASDAQ: KLRS) reported Q1 EPS of ($0.46).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• U.S., Canada discussing possible reduction in U.S. autos tariffs to 15% after some value content deductions from 25% currently - Reuters
• Anthropic revenue run rate surpasses $65 billion ahead of IPO - Bloomberg